Feed OZYMF
OZ

Strategic Partners A/S OZYMF OTC · Healthcare · Denmark

$90.00 +0.00% +$0.00

Summary

35 / 100 · Bulios Score

What speaks for it

  • Out of every 100 DKK of revenue, 39 DKK is left as net profit.
  • It has no debt and holds 70.7K kr in cash.

What to watch

  • The share price is above the Bulios Fair Price.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks expensive
Bulios Fair Price
Overvalued Price today $90

By our assumptions the business is worth less than its shares cost today.

P/E today 209.2
Biotechnology industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 209.2 DKK for 1 DKK of yearly profit.

Valuation in detail

Is it growing?

It is shrinking

Revenue (DKK)

Diluted EPS (DKK)

There is not enough revenue history yet to say how fast it grows.

Growth in detail

Does it make money?

Very well

Where 100 DKK of revenue goes

Net profit, industry median (Biotechnology) -9.2 DKK

Out of every 100 DKK of revenue, 39 DKK is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

It has no debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly negative

No analyst has published a price target.

0.0% of the analysts recommend buying.

Analysts in detail

What does it earn on?

By product

The company reports no revenue by product.

By region

The company reports no revenue by region.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy